Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
ENA Respiratory
ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations
June 15, 2026
ENA Respiratory Successfully Completes First Part of Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
May 11, 2026
ENA Respiratory Appoints Melissa Faris to Board
April 23, 2026
ENA Respiratory Announces Dosing of First Participants in Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
January 29, 2026